L-5-Hydroxytryptophan-d3
(Synonyms: L-5-HTP-d3; Oxitriptan-d3) 目录号 : GC69348L-5-Hydroxytryptophan-d3 是 L-5-Hydroxytryptophan 的氘代物。L-5-Hydroxytryptophan (L-5-HTP) 是一种天然氨基酸和膳食补充剂，可作为抗抑郁剂、食欲抑制剂和睡眠辅助剂，是神经递质血清素的前体，是利血平 (reserpine) 的拮抗剂。L-5-Hydroxytryptophan (L-5-HTP) 可用于纤维肌痛症、肌阵挛、偏头痛和小脑共济失调的研究。
Cas No.:1276197-29-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
L-5-droxytryptophan-d3 is the deuterium labeled L-5-droxytryptophan. L-5-droxytryptophan (L-5-HTP), a naturally occurring amino acid and a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, is the immediate precursor of the neurotransmitter serotonin and a reserpine antagonist[1]. L-5-droxytryptophan (L-5-HTP) is used to treat fibromyalgia, myoclonus, migraine, and cerebellar ataxia[2][3][4][5].
Stable heavy isotopes of drogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.
[2]. ARVID CARLSSON, et al. 3,4-Didroxyphenylalanine and 5-droxytryptophan as Reserpine Antagonists. Nature 180, page1200 (1957).
[3]. Caruso I, et al. Double-blind study of 5-droxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res. 1990 May-Jun;18(3):201-9.
[4]. Thal LJ, et al. Treatment of myoclonus with L-5-droxytryptophan and carbidopa: clinical, electropsiological, and biochemical observations. Ann Neurol. 1980 Jun;7(6):570-6.
[5]. Boiardi A, et al. 5-OH-Tryptophane in migraine: clinical and neuropsiological considerations. J Neurol. 1981;225(1):41-6.
[6]. Trouillas P, et al. Improvement of cerebellar ataxia with levorotatory form of 5-droxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988 Nov;45(11):1217-22.
| Cas No. | 1276197-29-5 | SDF | Download SDF |
| 别名 | L-5-HTP-d3; Oxitriptan-d3 | ||
| 分子式 | C11H9D3N2O3 | 分子量 | 223.24 |
| 溶解度 | DMSO : 12.5 mg/mL (55.99 mM; ultrasonic and warming and heat to 60°C) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 4.4795 mL | 22.3974 mL | 44.7948 mL |
| 5 mM | 0.8959 mL | 4.4795 mL | 8.959 mL |
| 10 mM | 0.4479 mL | 2.2397 mL | 4.4795 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。